Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting [Yahoo! Finance]
Rallybio Corporation (RLYB)
Company Research
Source: Yahoo! Finance
advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California. "With our Phase 2 trial underway evaluating RLYB212 in pregnant women at higher risk of maternal alloimmunization and FNAIT, we are pleased that our collaborators at Versiti continue to add to the preclinical data showing RLYB212 has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models," said Stephen Uden, M.D., Chief Executive Officer of Rallybio. "Additionally, we are delighted to share, for the first time, preclinical data demonstrating the potential for RLYB332, our long-acting anti-matriptase-2 antibody, to be a best-in-class therapeutic for patients with diseases of iron overload
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual MeetingBusiness Wire
- Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025Business Wire
- Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women [Yahoo! Finance]Yahoo! Finance
RLYB
Earnings
- 8/8/24 - Beat
RLYB
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- RLYB's page on the SEC website